SK10582001A3 - Reverzné hydroxamátové inhibítory matricových metaloproteináz - Google Patents

Reverzné hydroxamátové inhibítory matricových metaloproteináz Download PDF

Info

Publication number
SK10582001A3
SK10582001A3 SK1058-2001A SK10582001A SK10582001A3 SK 10582001 A3 SK10582001 A3 SK 10582001A3 SK 10582001 A SK10582001 A SK 10582001A SK 10582001 A3 SK10582001 A3 SK 10582001A3
Authority
SK
Slovakia
Prior art keywords
phenyl
hydroxy
sulfonyl
ethyl
phenoxy
Prior art date
Application number
SK1058-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Michael L. Curtin
Yujia Dai
Steven K. Davidsen
Howard R. Heyman
James H. Holmes
Michael R. Michaelides
Douglas H. Steinman
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of SK10582001A3 publication Critical patent/SK10582001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK1058-2001A 1999-01-27 2000-01-27 Reverzné hydroxamátové inhibítory matricových metaloproteináz SK10582001A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23908799A 1999-01-27 1999-01-27
PCT/US2000/002038 WO2000044739A1 (en) 1999-01-27 2000-01-27 Reverse hydroxamate inhibitors of matrix metalloproteinases

Publications (1)

Publication Number Publication Date
SK10582001A3 true SK10582001A3 (sk) 2001-12-03

Family

ID=22900549

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1058-2001A SK10582001A3 (sk) 1999-01-27 2000-01-27 Reverzné hydroxamátové inhibítory matricových metaloproteináz

Country Status (28)

Country Link
US (1) US20020007060A1 (de)
EP (1) EP1147101B1 (de)
JP (1) JP4718686B2 (de)
KR (1) KR100748010B1 (de)
CN (1) CN1222519C (de)
AR (1) AR029329A1 (de)
AT (1) ATE228122T1 (de)
AU (1) AU764383B2 (de)
BG (1) BG105782A (de)
BR (1) BR0007278A (de)
CA (1) CA2358951C (de)
CO (1) CO5150194A1 (de)
CZ (1) CZ20012591A3 (de)
DE (1) DE60000819T2 (de)
DK (1) DK1147101T3 (de)
ES (1) ES2187443T3 (de)
HK (1) HK1043115A1 (de)
HU (1) HUP0105477A2 (de)
IL (1) IL143713A0 (de)
NO (1) NO20013669L (de)
NZ (1) NZ512372A (de)
PL (1) PL349771A1 (de)
PT (1) PT1147101E (de)
SK (1) SK10582001A3 (de)
TR (1) TR200102159T2 (de)
TW (1) TWI225486B (de)
WO (1) WO2000044739A1 (de)
ZA (1) ZA200104979B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
WO2003063762A2 (en) * 2001-01-12 2003-08-07 Abbott Laboratories Process for the preparation of matrix metalloproteinase inhibitors
ATE420068T1 (de) 2001-09-07 2009-01-15 Kaken Pharma Co Ltd Reverse hydroxamsäurederivate
EP2298733B1 (de) * 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilinderivate mit einer Hydroxyamino- oder Acyloxyaminocycloalkylgruppe
AU2008350907A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2015107139A1 (en) 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren

Also Published As

Publication number Publication date
NO20013669L (no) 2001-09-27
IL143713A0 (en) 2002-04-21
CA2358951A1 (en) 2000-08-03
CA2358951C (en) 2009-10-20
CN1339032A (zh) 2002-03-06
ES2187443T3 (es) 2003-06-16
TWI225486B (en) 2004-12-21
ZA200104979B (en) 2002-09-18
PT1147101E (pt) 2003-04-30
TR200102159T2 (tr) 2001-12-21
US20020007060A1 (en) 2002-01-17
CZ20012591A3 (cs) 2001-12-12
KR100748010B1 (ko) 2007-08-09
EP1147101B1 (de) 2002-11-20
JP4718686B2 (ja) 2011-07-06
BR0007278A (pt) 2001-11-27
CN1222519C (zh) 2005-10-12
AR029329A1 (es) 2003-06-25
WO2000044739A1 (en) 2000-08-03
HUP0105477A2 (hu) 2002-05-29
PL349771A1 (en) 2002-09-09
AU2739100A (en) 2000-08-18
KR20010101709A (ko) 2001-11-14
NZ512372A (en) 2003-01-31
CO5150194A1 (es) 2002-04-29
BG105782A (en) 2002-04-30
DE60000819D1 (de) 2003-01-02
DE60000819T2 (de) 2003-09-04
NO20013669D0 (no) 2001-07-26
EP1147101A1 (de) 2001-10-24
HK1043115A1 (zh) 2002-09-06
JP2002535398A (ja) 2002-10-22
ATE228122T1 (de) 2002-12-15
DK1147101T3 (da) 2003-03-10
AU764383B2 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
AU2017200135B2 (en) Anthelmintic compounds and compositions and method of using thereof
TWI309980B (en) C-glycoside derivatives or salts thereof
CA2932010C (en) Urea derivative or pharmacologically acceptable salt thereof
DE69633947T2 (de) Zwischenprodukte zur Herstellung von Metallproteinasehemmern
EP3558981B1 (de) Pyranderivate als inhibitoren von cyp11a1 (cytochrom-p450-monooxygenase 11a1)
JP3662941B2 (ja) マトリックスメタロプロテイナーゼのリバースヒドロキサメート阻害剤
CN103254119B (zh) 钠-葡萄糖协同转运蛋白2的抑制剂及其用法
KR20170010069A (ko) 고체 형태의 (2ｓ,3ｒ,4ｒ,5ｓ,6ｒ)-2-(4-클로로-3-(4-에톡시벤질)페닐)-6-(메틸티오)테트라히드로-2ｈ-피란-3,4,5-트리올 및 그의 사용 방법
WO2008016132A1 (en) Benzyl phenyl glucopyranoside derivative
EA026668B1 (ru) Новые бициклические пиридиноны
EP1308436B1 (de) Calciumrezeptor-antagonisten
SK10582001A3 (sk) Reverzné hydroxamátové inhibítory matricových metaloproteináz
US8143294B2 (en) 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors
WO2000044712A1 (en) N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
MXPA01007658A (en) Reverse hydroxamate inhibitors of matrix metalloproteinases
OA17714A (en) Anthelmintic compounds and compositions and method of using thereof.